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Background: Treatment of patients with acute mania remains a considerable medical challenge since onset of
action of antimanic medication is delayed for several days. Psychostimulants could have an earlier onset of action.
This assumption is based on the ‘vigilance regulation model of mania’ which postulates that vigilance is unstable in
manic patients. Accordingly, vigilance-stabilising psychostimulants could be more useful than conventional
treatment in acute mania. We present here the study protocol of a trial intended to study the efficacy and safety of
methylphenidate in the initial treatment of acute mania.
Methods/design: A multi-centre, randomised, double-blind, placebo-controlled clinical trial will be conducted in 88
bipolar inpatients with acute mania. Male and female patients older than 18 years will be randomised to treatment
with either methylphenidate (20 to 40 mg/day) or placebo for 2.5 days, given once or twice daily. The main
outcome measure is the reduction in the Young Mania Rating Scale (YMRS) after 2.5 days of treatment. Other
outcome measures include the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) the Clinical
Global Impression–Bipolar Scale (CGI-BP), the Screen for Cognitive Impairment in Psychiatry (SCIP), actigraphy and
the EEG-‘Vigilance Algorithm Leipzig’ (VIGALL).
Discussion: A positive study outcome of the proposed study could substantially impact our understanding of the
etiopathogenesis of mania and open new treatment perspectives.
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Treatment of patients with acute mania remains a conside-
rable medical challenge, amongst other reasons because
manic patients often lack insight into their illness and into
the necessity being treated. Therefore, there is a need for
rapidly acting antimanic substances since initial willingness
being treated may change and then seriously compromise
treatment outcome. Yet, onset of action of medication
commonly used in the treatment of mania is delayed for at
least several days (e. g. haloperidol, lorazepam, olanzapine,
risperidone, valproate) or more (e. g. lithium, carbamaze-
pine) [1-3]. Faster onset of action of antimanic medication
would not only shorten the burden of patients but also
significantly decrease cost due to shorter duration of
hospital stay [1].
While above mentioned substances are sedating, we
intend to use a rapidly acting, stimulating substance in
this study. This plan is based on the ‘vigilance regulation
model of mania’. It takes into account that the vigilance
level –vigilance defined as brain arousal– does not only
influence behaviour but that in turn, behaviour can also
affect the level of vigilance; i.e. a more/less stimulating
environment can be actively created in order to
increase/reduce vigilance levels. For example, overtired
children often develop a hyperactive, talkative and sensa-
tion seeking behaviour which can be interpreted as an
autoregulatory attempt to stabilise vigilance by increasing
external stimulation. We postulate that this physiological
autoregulatory mechanism may result in a pathological
behavioural syndrome, namely mania, in vulnerable
subjects [4-6]. The autoregulatory mechanism might over-
ride the physiological tendency to seek sleep, thus aggra-
vating sleep deficits, worsening vigilance instability and
thereby starting a vicious circle ending up in full-blown
mania (Figure 1) [4].
The outlined model has already been proposed earlier
[7,8] and is related to personality theories about extra-
version [9] and sensation seeking [10] which comparablyFigure 1 The vigilance regulation model of mania: Unstable vigilance
leading to full-blown mania. Figure taken from: Hegerl U., et al. Are psyc
42:169-174. Reproduced with kind permission of Georg Thieme Verlag KG”.explain these traits as an attempt to compensate for low
central nervous system arousal.
The ‘vigilance regulation model of mania’ provides an
explanation for several seemingly paradoxical aspects
and is supported by several lines of evidence:
 In contrast to the clinical observation of hyperactivity,
there is robust evidence from EEG recordings that
vigilance is unstable in manic patients: under quiet
rest, manic patients show rapid decline to low
vigilance stages often already within the first seconds
of EEG recording [4]. In line with this, micro sleeps
(abrupt intrusion of sleep spindles) were observed
shortly after starting recordings [11,12].
 Sleep deficits can trigger or worsen manic behaviour
[13,14] and life events disturbing sleep-wake
-regulation can trigger or aggravate (hypo)manic
syndromes [15]. Accordingly, stabilisation of sleep-
wake rhythm is used in behavioural therapies for
bipolar disorder [13,16].
 Withdrawal of vigilance-stabilising drugs, such as
nicotine, can trigger mania [17,18] and a high
smoking prevalence has been reported in bipolar
disorder [19]. This may indicate that these patients
may benefit from the vigilance-stabilising properties
of nicotine. Consistently, smoking and coffee
drinking were not associated with higher incidence
of mania in bipolar disorder, when confounding
factors were controlled for [20].
 In ADHD, a disease with high comorbidity and a
broad symptom overlap with mania [21,22],
psychostimulants effectively reduce attention
deficits, sensation seeking behaviour and
hyperactivity, symptoms which are also present in
mania [23,24]. In addition, methylphenidate has
been shown to improve sleep in children [25,26] and
adult patients [27] with ADHD. Furthermore,
randomised controlled trials in pediatric patientsinduces a pathogenic circle with vigilance stabilisation syndrome
hostimulants a treatment option in mania? Pharmacopsychiatry 2009;
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showed that psychostimulants are effective in
reducing both ADHD and manic symptoms [28,29].
 There is increasing evidence that psychostimulants
are effective in treating mania and that this effect is
related to stabilisation of vigilance. A variety of case
reports describe a pronounced and rapid
improvement of manic symptoms after
administration of psychostimulants in adult manic
patients with bipolar disorder [4,30-33]. Bschor et al.
[34] report on a manic patient with decreased
vigilance who showed both a rapid (within 2 hours)
and strong improvement of manic symptoms and a
stabilisation of vigilance as assed in the EEG after
administration of methylphenidate.
 Good response to the psychostimulant modafinil
was recently described in a case report. Clinical
improvement was observed already after one hour
and it was associated with a stabilisation of vigilance
[35]. In line with our model, psychostimulants were
mostly not efficacious in the treatment of typical
depression, except for apathy [36,37].
While psychostimulants have occasionally been linked
to induction of mania [38] switches into mania occur
rarely: A large evaluation by the U.S. Food and Drug
Administration found a psychotic or manic-like reaction
only in about 1 of 400 treated patients with ADHD and
in the majority of cases (> 90%) the symptoms resolved
within 2 days. Thus, the risk of an aggravation of manic
symptoms appears to be low [39].
Onset of action of methylphenidate is fast, i.e. faster
than 1 hour and maximum effects will be reached after
approximately 2 hours [40]. Thus, methylphenidate is
likely to provide a much faster effect on manic symptoms
than other drugs commonly used in mania.
Taken together, there is increasing evidence from both
case studies in adult manic patients and randomised
controlled trials in pediatric patients with ADHD and
concomitant manic symptoms that psychostimulants
such as methylphenidate are effective in the rapid
treatment of mania.
Aim of this study, the ‘Methylphenidate in Mania
project’ (MEMAP), is to test for the first time the
hypothesis that the psychostimulant methylphenidate
has antimanic properties after 2.5 days of treatment
using a double-blind placebo-controlled design.
Research objectives
Primary objective
The primary objective of the study is to test the hypothesis
that methylphenidate immediate release given twice daily
(BID) is significantly superior to placebo in the treatment
of manic symptoms in patients with bipolar disorder after2.5 days of treatment as assessed by the Young Mania
Rating Scale (YMRS) [41].
Secondary objectives
Secondary objectives of this study comprise to evaluate
 Whether methylphenidate immediate release given
BID is significantly superior to placebo in the
treatment of manic symptoms in patients with bipolar
disorder after 2 hours of treatment as assessed by the
YMRS and the Positive and Negative Syndrome scale
- excited component (PANSS-EC) [42].
 The change from baseline to endpoint (after 2.5 days of
treatment) on the Clinical Global Impression-Bipolar
Scale CGI-BP [43] and the PANSS-EC.
 Whether 2.5 days of treatment with
methylphenidate but not with placebo stabilise
vigilance regulation as assessed by the ‘Vigilance
Algorithm Leipzig’ (VIGALL) [44].
 Whether instability of vigilance regulation as
assessed by the VIGALL predicts response to
methylphenidate.
 Whether methylphenidate immediate release given
BID is associated with significantly less movements
over the study period than placebo as assessed by
actigraphy.
 Whether methylphenidate is significantly superior to
placebo in improving cognitive performance as
assessed by the “Screen for Cognitive Impairment in
Psychiatry” (SCIP) [45].
Methods and design
Design
MEMAP is a two-arm, randomised, placebo-controlled,
double-blind, parallel, multi-centre phase IIIb exploratory
study to evaluate the efficacy and safety of methylphenid-
ate in the initial treatment of acute mania in patients with
bipolar affective disorders. After being screened for eligi-
bility and signing the informed consent (day -2 or day -1),
patients will be randomised to either 2.5 day treatment
with methylphenidate BID or placebo BID at a 1:1 ratio
(day -1/day 0). Medication will be administered at 10.00
and 15.00 h on day 0 (15 mg methylphenidate or placebo
BID), at 09.00 and 15.00 h on day 1 (20 mg methylphenid-
ate or placebo BID), and at 09.00 h on day 2 (20 mg
methylphenidate or placebo). EEG should be conducted
prior to first medication and 2 h after the morning dose
on day 2. Manic symptoms will be assessed using the
YMRS. YMRS will be scored at baseline and 2 h after the
morning dose on every day. In addition, the CGI-BP and
PANSS-EC will be scored. Furthermore, movements will
be recorded using actigraphy and a cognitive test (SCIP)
[45] will be performed. The schedule of study assessments
is described in detail in Table 1.
Table 1 Schedule of study assessments
Examination/evaluation Screening Treatment Follow up
Day -2/-1 0 1 2 3 9
Review Inclusion/Exclusion criteria X
Informed consent X
Randomisation *X (X)
General
Medical and psychiatric history X
Demographics and illness characteristics X
Physical examination X
Vital signs X X X X X X
Blood analysis X X X
Urine analysis, drug screening X X
Pregnancy test *X
Concomitant medication X X X X X
Baseline findings/adverse events X X X X X
ECG X X X
ADHD-Screening X
Efficacy
YMRS X XX X X X X
CGI-BP X X X X
PANSS-EC XXXXX X X X X
EEG X X
Actigraphy *X X X X
Cognitive test X X X
Medication
Study drug: methylphenidate, placebo X*X* X**X** X**
Up to 3 mg/day lorazepam or alprazolam X
Up to 2 mood-stabilisers allowed X X X X X X
*day -1 after informed consent.
Number of ‘X’ represents number of assessments (X* 15 mg methylphenidate vs. placebo, X** 20 mg methylphenidate vs. placebo).
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disorder that has been stable for at least 4 weeks includ-
ing benzodiazepines, lithium, anticonvulsants or antipsy-
chotics will be continued in the same dose. Only
patients receiving up to 2 such drugs are eligible for
study participation. During screening, the (additional)
use of up to 3 mg/day lorazepam or alprazolam is
allowed. The treatment period is 2.5 days. There will be
two post treatment visits at day 3 and 9.
Ethics
This international study will be conducted in
Belgium, Germany, Hungary and Spain. Study spon-
sor is the University of Leipzig, Germany. The study
protocol has been already approved by both the
leading Ethics Committees (EC) and Health Autho-
rities in Germany, Hungary and Spain as well as theresponsible Health Authority in Belgium. The investi-
gator is responsible for ensuring that no patient is
subject to any study-related examination or activity
before that patient has given written informed con-
sent, after the receipt of detailed information. The in-
vestigator will inform the patient of the aims,
methods, anticipated benefits and potential hazards of
the study including any discomfort it may entail. This
information will be summarized in integrated patient
information and consent sheets. The study has been
registered on the EudraCT database (EudraCT
number 2010-023992-24) and at ClinicalTrials.gov
(NCT01541605). The trial will be conducted in accor-
dance with the latest version of the Declaration of
Helsinki and the International Conference on Harmo-
nization (ICH) - Good Clinical Practice (GCP) guidelines
for clinical trials.
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The study population will comprise 88 adults of either
sex with the diagnosis of a manic episode according to
ICD-10, 44 in each arm of the study. To be included in
the study, patients must fulfil all inclusion criteria and
not meet an exclusion criterion.
Inclusion criteria are: 1. inpatients; 2. written informed
consent by patients who are competent to consent to study
participation; 3. diagnosis of a manic episode according to
ICD-10 classification (F30.0, F30.1, F31.0 or F31.1); 4. male
or female ≥ 18 years of age; 5. YMRS total score ≥ 20
and ≤ 45 points; 6. body mass index (BMI) > 17 and 7.
patients must be able to swallow tablets (study drug).
Exclusion criteria are: 1. any other current major psychi-
atric ICD-10 disorder except for attention deficit hyper-
activity disorder (ADHD) or other hyperkinetic disorders
(F90), harmful use of tobacco (F17.1), dependence
syndrome of tobacco (F17.2), neurotic, stress-related and
somatoform disorders (F40-48), behavioural syndromes
associated with physiological disturbances and physical
factors (F50-F59) or disorders of adult personality and
behaviour (F60-F69); 2. contraindications for treatment
with methylphenidate except as noted otherwise including
hypersensitivity to methylphenidate or components of the
drug, patients with extreme anxiety and agitation, women
with child bearing potency without effective contraception
(i. e. implants, injectables, combined oral contraceptives,
some IUDs or vasectomised partner) during the conduct of
the trial. Patients using hormonal methods of contraception
must be informed about possible influences of the study
drug on contraception; 3. serious non-psychiatric
disease (e.g. infectious, autoimmune or metabolic), that
may interfere with the objectives of the study or with the
safety or compliance of the subject, as judged by the inves-
tigator; 4. oral administration of MAO-inhibitors within
two weeks, fluoxetine within 6 weeks and of any other
antidepressant or primarily psychotropic substance except
for those specified below within one week before study
entry; 5. stable treatment with mood stabilisers including
lithium, anticonvulsants (e.g. valproate, carbamazepine) or
antipsychotics (e.g. risperidone, olanzapine) or benzo-
diazepines is NOT an exclusion criterion and will be
continued; however, patients receiving more than 2 of
these substances are NOT eligible for inclusion; 6. medical
history of other disorders of CNS including tics or dyskin-
esia; 7. medical history of cardiovascular diseases, severe
hypertension, glaucoma, hyperfunction of the thyroid; 8.
patients with congenital or acquired long QT syndrome,
or with a familiy history of QT prolongation, sudden
cardiac death or other significant inherited cardiac
disorders (e.g. family history of hypertrophic cardiomyo-
pathy); 9. history of Electroconvulsive therapy within the
last 3 month; 10. known alcohol and drug addiction or
abuse, except for patients with abstinence > 3 month.Patients with sporadic abuse of cannabis (products)
will not be excluded from the study. That is even true
with a positive THC screen in urine; 11. pregnant or
nursing women; 12. concomitant participation in other
clinical trials or participation during the 30 days prior
to screening; 13. prior participation in this study or
14. suicidality.
Outcome measures
Primary outcome measure
The primary outcome measure is the severity of manic
symptoms as assessed by the Young Mania Rating Scale
(YMRS) [41]. The YMRS is a clinician-administered mania
rating scale. It has 11 items and is based on the patient’s
subjective report of his or her clinical condition, normally
over the previous 48 hours. In this study, the period is
usually since the last scoring; at baseline and day 9 the
scoring refers to the last 24 hours. Additional information
is based upon clinical observations made during the
course of the clinical interview. The items being scored
are elevated mood, increased motor activity-energy, sexual
interest, sleep, irritability, speech (rate and amount),
language-thought disorder, content, disruptive-aggressive
behaviour, appearance, and insight. The purpose of each
item is to rate the severity of that abnormality in the
patient. A score of ≥ 12 indicates mania. The primary
endpoint is after 2.5 days of treatment.
Secondary outcome measures
Secondary outcome variables comprise:
 Clinical impression as assessed by the Clinical
Global Impressions Scale Bipolar version (CGI–BP)
[43]. This is a modified version of the Clinical
Global Impressions Scale (CGI) specifically for use
in assessing global illness severity and change in
patients with bipolar disorder. It will be rated twice,
before first and after last treatment.
 Severity of agitation as assessed by the Positive and
Negative Syndrome scale - excited component
(PANSS-EC) [42]. The PANSS–EC is an easy and
fast to administer and easy to record scale for
assessment of excitation and agitation including five
items: poor impulse control, tension, hostility,
uncooperativeness and excitement. It has been
validated and is appropriate for repeated measures
and will be scored up to 5 times per visit.
 EEG-vigilance as assessed by the ‘Vigilance
Algorithm Leipzig’ (VIGALL) [44]. The VIGALL
is an algorithm using topographic and spectral
EEG-information for classifying different stages of
wakefulness ranging from alertness over drowsiness
to sleep. During stages A and B subjects are awake,
during stage C asleep. Stages and sub-stages are
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(A1: high occipital alpha power, A2: high overall
alpha power, A3: high frontal alpha power); stage B:
alpha absent (B1: ‘flat’ desynchronised EEG, B2/3:
high delta/theta power); stage C: K-complexes or
sleep spindles. Resting EEGs will be conducted
twice, before first and after last treatment.
 Total amount of movements over the study period
as assessed by actigraphy.
 Cognitive performance as assessed by the “Screen
for Cognitive Impairment in Psychiatry” (SCIP) [45].
The SCIP was designed for detecting cognitive
deficits in several psychotic and affective disorders.
It may be administered without the need for
additional equipment (only pencil and paper) and
requires nearly 15 min. Three alternative forms of
the scale are available to facilitate repeated testing
while minimising learning effects. The SCIP includes
a Working Memory Test, a Verbal Learning Test-
Immediate, a Verbal Fluency Test, a Verbal Learning
Test-Delayed, and a Processing Speed Test. The
SCIP will be performed three times, at baseline at
day 1 and day 2.
Other assessments
In addition, demographics (age, sex, ethnic origin) and
vital signs (blood pressure, heart rate) will be captured.
Blood analyses including haematology, clotting status
and serum chemistry as well as urinalyses (dip stick and
drug-screening) will be performed. Cardiac function will
be monitored using a 12-lead ECG. Adverse events will
be captured in the afternoon of each visit. For that, the
patient will be asked a non-leading question such as
‘Have you had any health problems today/since you were
last asked?’ For retrospective assessing of ADHD
symptoms in childhood, the Wender Utah Rating Scale
(WURS)-25 item version will be used [46].
Randomisation
Subjects will be randomised on day -1 or 0 to either
treatment arm after confirmation that the subject is
eligible for the study. There will be a block randomisa-
tion. Every site will initially receive an even number of
with a MedCode (e.g. 1000-1) consecutively numbered
blisterpacks, half of them containing verum, the other
half containing placebo. The block size ranges from 2
(alternating verum and placebo) to 6 (up to 3 times
placebo/verum in a row). The number of blocks and the
block size are unknown to the sites. Blisterpacks have to
be used in ascending order, i.e. the first patient to be
randomised receives the blisterpack with the lowest
number. Immediately after randomisation (not later than
2 h), the clinical trial center of the Sponsor has to be
informed about randomisation by fax.Statistics
Determination of sample size
Since there are no double-blind studies comparing treat-
ment with methylphenidate and placebo in manic patients
the following considerations have been taken into account:
1. The vigilance regulation capacity varies among manic
patients: 35% of patients are expected to have a
markedly instable vigilance regulation and therefore
are expected to strongly respond [38]. In these cases
a remission of manic symptoms after 2.5 days of
treatment with methylphenidate will be
operationalized as 14 points decrease in the YMRS.
35% of patients are expected to have a partially
instable vigilance regulation and the expected
treatment response is 7 points YMRS decrease; 30%
of patients are expected to have a stable vigilance
regulation and in these patients the response to
treatment is expected to be 3 points YMRS decrease
(placebo level);
2. Expected placebo effect after 2.5 days of treatment:
3 ± 2 points on the YMRS;
3. Expected drop out rate: 5% at maximum considering
the study design (short duration, inpatients).
For the statistical testing of the primary study objective
a statistical power of 1- β = 0.8, and a significance level
of α = 0.05 are envisaged. Using these assumptions, the
number of patients per treatment group was calculated
as follows: ([z1 + z2]
2 x [σ1
2 + σ2
2])/(μ1 – μ2)
2; z1: 0,96
(type I error of 5%); z2: 0,842 (power of 80%), μ1:
mean verum group: 7.9, μ2: mean placebo group: 3, σ1: SD
verum group 4.7, σ2: mean placebo group 2). According to
this calculation, 42 patients per treatment group will be
required + 5% (= 2 patients) for dropouts. Thus, 44
patients per group will be required. It is therefore planned
to recruit a total of 88 patients into the study. Since the
empirical basis for this power analysis is small, an adaptive
interim analysis will be performed after inclusion of 20
patients per study arm with the following rules [47]:
 Early stopping due to futility, i.e. it is unlikely that
the null hypothesis (Ho) can be rejected with a
larger sample size (p1 ≥ 0.30 (α0));
 Early stopping with rejection of the null hypothesis
(Ho) (p1 ≤ 0.03 (α1));
 Re-estimation of the sample size in case of
continuation (if p1 ∈ (α1,α0)).
Analysis
The Full Analysis Set (FAS) consists of all patients of the
randomised population who receive at least one dose of
treatment in either group regardless of protocol
deviations. All analyses will be conducted on the FAS
Kluge et al. BMC Psychiatry 2013, 13:71 Page 7 of 9
http://www.biomedcentral.com/1471-244X/13/71unless otherwise specified. Supportive analyses on the
Per Protocol (PP) analysis set will be conducted for the
primary outcome. The PP consists of all patients of the
FAS who complete the study and do not have major
protocol violations.
The primary endpoint (mean change from baseline in
the YMRS total score at day 2) will be analyzed by
ANCOVA. Covariables include sex, age and severity of
illness at baseline. Secondary efficacy measures such as
change in YMRS total score from baseline at day 2, drop-
out rates, or the relationship between the stability of
vigilance regulation before treatment and response to
methylphenidate as well as the effects of methylphenidate
on the vigilance regulation will be analyzed using descrip-
tive statistics. The statistical hypothesis test of the primary
and secondary variables will be used at a significance level
of 0.05 (two-sided).
Statistical evaluations will be performed by using
SPSSW Version PASW 20.
Discussion
Based upon previous reports on the benefit of psych-
ostimulants in the treatment of mania and upon the
‘vigilance regulation model of mania’, we present here the
study protocol of the ‘Methylphenidate in Mania project’
(MEMAP), a randomised double blind placebo-controlled
trial to test the effectiveness of methylphenidate in the
early treatment of mania.
During study protocol development, the following
considerations have been made:
The screening visit on day -2 or day -1 and first treat-
ment on day 0 accommodates both the need for an early
treatment and the ICH Guideline for Good Clinical
Practice requirement to provide the subject “ample time
and opportunity to inquire about details of the trial and
to decide whether or not to participate in the trial” [48].
In addition, it allows checking routine laboratory values
and plasma levels of concomitant medication prior to
first study drug administration. Furthermore, an initial
placebo effect through arrival on the ward will not be
considered when baseline evaluations are performed one
day after arrival and not on the day of arrival. Manic
symptoms will be assessed throughout 2 h after study
drug intake to make sure that changes are not related to
grossly different plasma levels. In addition, manic
symptoms will be always assessed in the morning (12.00
at baseline, 11.00 h all other evaluations) to minimize
influences of circadian mood changes.
The maximum dose of 20 mg twice daily analogous to
0.29 mg/kg (daily total dose: 40 mg ≈ 0.58 mg/kg) is lower
than in the majority of 26 studies listed in a recent
systematic review on the safety of therapeutic methyl-
phenidate in adults [49] which considers methylphenidate
safe in the dose range from 20 to 90 mg/day. Overall,we therefore do not expect a significantly higher fre-
quency of side effects.
The administration of methylphenidate in addition to
pre-existing mood-stabilising medication is expected to
be well tolerated as this has been shown for combination
therapy with other psychotropic drugs [36,37].
The short duration in this study in which patients may
not receive established antimanic medication of 4.5 days
at maximum (screening + treatment period), being shorter
than usual wash-out or placebo run in-periods of 7 days
in other studies in the same indication [50,51], justifies the
treatment with placebo in the half of the patients. That is
particularly true since inpatients will be closely monitored
by specialised psychiatry staff allowing an immediate
intervention in case of a substantial worsening of mania.
Since methylphenidate has been shown and is expected
to act very rapidly [40], a treatment duration of 2.5 days
has been considered sufficient.
While the study may yield the results that methyl-
phenidate is in principle efficacious in the treatment of
mania, the short study duration does not allow drawing
any conclusions about efficacy and safety in the longer
term what is a limitation.
In conclusion, we propose here a randomised double
blind placebo-controlled study to test the efficacy and
safety of methylphenidate in the early treatment of mania
based upon the ‘vigilance regulation model of mania’. A
positive study outcome could substantially impact our
understanding of the etiopathogenesis of mania and open
new perspectives in its treatment.
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